睡眠障碍治疗市场－2026-2031年预测

预计睡眠障碍治疗市场将从 2025 年的 198.78 亿美元成长到 2031 年的 356.66 亿美元，复合年增长率为 10.23%。

由于全球失眠和其他睡眠障碍的发生率不断上升，睡眠障碍治疗市场需求日益增长。忧郁症、焦虑症和心理创伤发病率的上升，以及饮酒和气喘导致的睡眠模式紊乱，进一步推动了市场成长。透过睡眠健康宣传活动和教育活动意识提升，也促进了市场的发展势头。

睡眠障碍的治疗方法因病因而异，通常包括药物治疗、生活方式调整和饮食习惯改变。主要驱动因素包括某些药物相关睡眠障碍病例的增加以及频尿等因素。未经治疗的睡眠问题所带来的副作用，例如嗜睡和易怒，凸显了有效治疗方法的必要性，并推动了市场扩张。

关键成长要素包括忧郁症和焦虑症的日益普遍（其中失眠通常是核心症状），以及由心理和生理创伤和合併症引起的睡眠障碍，这些因素也推动了对有针对性的治疗方法的需求。

气喘病例的增加和酒精消费量的成长也推动了市场成长。气喘药物及其相关併发症会加剧失眠，而过量饮酒则会损害睡眠的数量和质量，从而经常导致失眠。

由于睡眠障碍的高发生率以及公众对其危害的日益关注，存在着许多机会。持续的宣传活动在促进治疗方法普及方面发挥着至关重要的作用。例如，睡眠基金会已连续25年举办“睡眠意识週®”，旨在传播睡眠模式数据以及基于实证的睡眠对健康影响指导。此外，生活水准的提高和人们健康意识的增强也扩大了市场潜力，并为创新和新进入者创造了机会。

从地理上看，北美预计在预测期内将保持显着的市场份额。这一主导地位主要得益于较高的疾病认知度和诊断率，以及快节奏的生活方式所导致的压力和睡眠问题。此外，主要行业参与者的存在，透过提供先进的治疗方案和便利的医疗服务，进一步推动了该地区的成长。

睡眠障碍治疗领域的主要企业包括辉瑞公司，该公司致力于推动医疗创新，并提供适用于各年龄层睡眠障碍的Sonata®（Zaleplon）胶囊等产品。总部位于日本的全球研发主导企业武田药品工业株式会社提供获得美国食品药品监督管理局（FDA）核准的非处方睡眠药物Rozerem™，该药物选择性地靶向大脑视交叉上核（SCN）中的受体。

总体而言，市场正在迅速扩张，透过多方面的方法解决睡眠健康方面的关键缺口，将药物解决方案与行为和教育策略相结合，以应对人口结构和生活方式变化带来的挑战。

本报告的主要优势：

• 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
• 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
• 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
• 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
• 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

• 历史资料（2021-2025 年）和预测资料（2026-2031 年）
• 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
• 竞争对手定位、策略和市场占有率分析
• 按业务板块和地区（国家）分類的收入成长和预测分析
• 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 分析范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策和法规
• 策略建议

第四章 技术展望

第五章：按药物类型分類的睡眠障碍治疗市场

• 介绍
• 苯二氮平类药物
• 非苯二氮平类药物
• 抗忧郁症
• Orexin拮抗剂
• 褪黑素拮抗剂
• 其他药物类型

第六章：按应用分類的睡眠障碍治疗市场

• 介绍
• 失眠
• 睡眠呼吸中止症
• 嗜睡症
• 昼夜节律紊乱
• 其他用途

第七章 按支付方分類的睡眠障碍治疗市场

• 介绍
• 公共医疗保险
• 私人医疗保险

8. 各地区睡眠障碍治疗市场

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 企业合併、协议、商业合作
• 竞争对手仪錶板

第十章：公司简介

• Dr Reddy's Laboratory
• Merck & Co.
• Pfizer
• Sanofi SA
• Takeda Pharmaceuticals Inc.
• Teva Pharmaceuticals Inc.
• Vanda Pharmaceuticals Inc.
• Sleep Health Solutions
• Cleveland Clinic
• Mayo Clinic

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 分析方法
• 简称

The sleep disorder treatment market is forecasted to achieve a 10.23% CAGR, reaching USD 35.666 billion in 2031 from USD 19.878 billion in 2025.

The sleep disorder treatment market is witnessing rising demand driven by increasing prevalence of insomnia and other sleep disturbances worldwide. Growth is further fueled by higher rates of depression, anxiety, and psychological trauma, alongside disruptions to sleep patterns from alcohol consumption and asthma. Expanding public awareness through dedicated sleep health campaigns and educational initiatives is also contributing to market momentum.

Treatments for sleep disorders vary based on underlying causes and typically combine medical interventions with lifestyle and dietary modifications. Key drivers include escalating sleep disorder cases linked to factors such as certain medications and frequent urination. The adverse effects of untreated sleep issues, including drowsiness and irritability, underscore the need for effective therapies, propelling market expansion.

A significant growth driver is the growing prevalence of depression and anxiety, where insomnia often manifests as a core symptom. Sleep disruptions can also stem from psychological or physical trauma and comorbid health conditions, positively influencing demand for targeted treatments.

Rising asthma cases and alcohol consumption further accelerate market growth. Asthma medications and associated comorbidities can exacerbate insomnia, while excessive alcohol intake impairs both sleep quantity and quality, frequently leading to insomnia.

Opportunities abound due to the high prevalence of sleep disorders and heightened public awareness of their detrimental effects. Ongoing awareness programs play a pivotal role in driving adoption of treatments. For instance, the Sleep Foundation has organized Sleep Awareness Week(R) annually for over 25 years, disseminating data on sleep patterns and evidence-based guidance on its health impacts. Additionally, rising living standards and greater health consciousness among populations are augmenting market potential, creating avenues for innovation and entry.

Geographically, North America is anticipated to maintain a significant market share during the forecast period. This dominance is supported by elevated disease awareness and diagnosis rates, coupled with demanding lifestyles that contribute to stress and sleep issues. The presence of major industry players further bolsters regional growth through advanced therapeutic options and accessibility.

Leading companies in the sleep disorder treatment sector include Pfizer, which advances medical innovation with offerings such as Sonata(R) (zaleplon) capsule CIV, suitable for sleep disturbances across younger and elderly demographics. Takeda Pharmaceuticals, a global research-driven entity based in Japan, provides Rozerem(TM), an FDA-approved non-scheduled prescription sleep medication that selectively targets receptors in the brain's suprachiasmatic nucleus (SCN).

Overall, the market is expanding rapidly, addressing critical gaps in sleep health through a multifaceted approach that integrates pharmacological solutions with behavioral and educational strategies, amid evolving demographic and lifestyle challenges.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Sleep Disorder Treatment Market Segmentation

• By Drug Type
• Benzodiazepines
• Nonbenzodiazepines
• Antidepressants
• Orexin Antagonists
• Melatonin Antagonists
• Other Drug Types
• By Application
• Insomnia
• Sleep Apnea
• Narcolepsy
• Circadian Disorders
• Other Applications
• By Payor
• Public Health Insurance
• Private Health Insurance
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SLEEP DISORDER TREATMENT MARKET BY DRUG TYPE

• 5.1. Introduction
• 5.2. Benzodiazepines
• 5.3. Nonbenzodiazepines
• 5.4. Antidepressants
• 5.5. Orexin Antagonists
• 5.6. Melatonin Antagonists
• 5.7. Other Drug Types

6. SLEEP DISORDER TREATMENT MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Insomnia
• 6.3. Sleep Apnea
• 6.4. Narcolepsy
• 6.5. Circadian Disorders
• 6.6. Other Applications

7. SLEEP DISORDER TREATMENT MARKET BY PAYOR

• 7.1. Introduction
• 7.2. Public Health Insurance
• 7.3. Private Health Insurance

8. SLEEP DISORDER TREATMENT MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Dr Reddy's Laboratory
• 10.2. Merck & Co.
• 10.3. Pfizer
• 10.4. Sanofi SA
• 10.5. Takeda Pharmaceuticals Inc.
• 10.6. Teva Pharmaceuticals Inc.
• 10.7. Vanda Pharmaceuticals Inc.
• 10.8. Sleep Health Solutions
• 10.9. Cleveland Clinic
• 10.10. Mayo Clinic

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations